Novo Nordisk Exits Inflammation R&D To Focus More On Diabetes, Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish insulin maker’s decision triggered by failure of its most advanced compound, anti-IL-20, for the treatment of rheumatoid arthritis.
You may also be interested in...
Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.